PRODUCTION METHOD OF BRUCELLAR MONOSPECIFIC SERUM ANTI-MELITENSIS Russian patent published in 2017 - IPC A61K39/10 A61K39/395 A61P31/00 

FIELD: veterinary medicine.

SUBSTANCE: provide the immunizations of rabbits with a single dose of B. melitensis strain. The rabbits immunization is carried out subdermally in the dewlap area with suspension of 1 ml volume, which contains:. 200 million MK inactivated culture of B. melitensis strain 16M with adjuvant MONTANIDE™ ISA 61 VG. At the 14th-16th day the trial blood collecting is conducted, and at the 21st-45th day the three-time blood collecting is carried out and at the 60th day it is dehematized. The serum is obtained and inactivated at 60-65°C during 1-1.5 hours. The cross adsorption with bacteriological weight of B. abortus 544 strain is carried out, obtained by culture growing within 70-72 hours. Centrifuge with cooling the residue during 24-26 hours, adding to the residue the physiological solution for obtaining the bacterial weight in the amount of 3.5-3.7×10⁹ pfu per 10 ml of serum. Further incubate at 37°C for 2 hours and restore the serum by centrifugation with further preserving and packaging.

EFFECT: utilisation of this method allows the use the inactivated Brucella culture to produce a monospecific serum, and take blood from each of the rabbits for at least four-times, increasing the amount of the resulting serum.

2 ex, 8 tbl